OBESITY/TYPE 2 DIABETES
NEWS
The TRANSECEND trial confirms that the melanocortin-4 receptor agonist setmelanotide achieves a significantly greater reduction in BMI and hunger than placebo in children, adolescents and adults with acquired hypothalamic obesity.
Glucose–insulin impairment in small-for-gestational-age children is comparable to that found in children with obesity and worsened by use of growth hormone therapy, say German researchers.
Use of the glucagon-like peptide -1 receptor agonist liraglutide alongside diet and exercise guidance significantly reduces BMI in children aged 6 to 11 years with severe obesity compared with lifestyle interventions alone, shows the SCALE Kids Trial.
Phase 2 trial results support use of the melanocortin-4 receptor agonist setmelanotide for the treatment of rapid excess weight gain and hunger in patients with hypothalamic obesity.
In depth
In our latest podcast, Professor Sadaf Farooqi discusses the most recent findings from the Genetics Of Obesity Study, and what they mean for families and children with severe early-onset obesity.
Programme Director Professor Martin Savage is joined by experts to present and discuss the application of precision medicine in endocrine disorders, offering clinical expertise and insight, evidence and opinion on this topic.
A 6 years and 5-month-old girl with Prader-Willi Syndrome attends endocrine clinic with her mother.
Dr Cheri Deal discusses the use of growth hormone in children with Prader-Willi syndrome, the importance of multidisciplinary care and the future of treatment for this genetic condition.
